547 related articles for article (PubMed ID: 24337110)
1. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity.
Martin JL; Lin MZ; McGowan EM; Baxter RC
J Biol Chem; 2009 Sep; 284(38):25542-52. PubMed ID: 19633297
[TBL] [Abstract][Full Text] [Related]
4. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Wang S; Liang Y; Chang W; Hu B; Zhang Y
Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826
[TBL] [Abstract][Full Text] [Related]
5. Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer.
Marzec KA; Baxter RC; Martin JL
Biomed Res Int; 2015; 2015():638526. PubMed ID: 26221601
[TBL] [Abstract][Full Text] [Related]
6. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.
Acharya S; Yao J; Li P; Zhang C; Lowery FJ; Zhang Q; Guo H; Qu J; Yang F; Wistuba II; Piwnica-Worms H; Sahin AA; Yu D
Cancer Res; 2019 Aug; 79(16):4211-4226. PubMed ID: 31239273
[TBL] [Abstract][Full Text] [Related]
8. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
11. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
14. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.
de Silva HC; Lin MZ; Phillips L; Martin JL; Baxter RC
Cell Mol Life Sci; 2019 May; 76(10):2015-2030. PubMed ID: 30725116
[TBL] [Abstract][Full Text] [Related]
15. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion.
Shida D; Fang X; Kordula T; Takabe K; Lépine S; Alvarez SE; Milstien S; Spiegel S
Cancer Res; 2008 Aug; 68(16):6569-77. PubMed ID: 18701480
[TBL] [Abstract][Full Text] [Related]
17. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
18. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
[TBL] [Abstract][Full Text] [Related]
19. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
20. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
